and Medicis Pharmaceutical Company today announced that the two companies have entered into a analysis and development contract to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne. Medicis shall have a choice to obtain an exclusive license for products covered by the agreement. Anacor shall be qualified to receive future research, development, regulatory and product sales milestones of up to $153 million, in addition to high single-digit to low double-digit royalties on sales by Medicis. Medicis will lead to further development and commercialization of the licensed products on an internationally basis.To capitalize, NTRR is working alongside innovative partners to deliver game-changing solutions for cannabis growers, retailers and patients. The company is creating a diverse type of products for each niche in the marketplace to be able to capture the largest share possible of the red-hot marketplace. By providing a number of new technologies designed to ensure safer, more reliable usage of cannabis in approved markets, Neutra Corp. Plans to enjoy unprecedented growth in 2014 alongside Cannabis Technology, Inc. , GW Pharmaceuticals, plc and CannaBusiness Group, Inc.